rAAV2-CB-hRPE65: Phase I data

A Phase I trial in 3 patients with Leber congenital amaurosis type 2 showed uniocular subretinal injection of rAAV2-CB-hRPE65 did not produce vector-related serious adverse events or systemic toxiciti...